Compare AbCellera Biologics Inc (ABCL) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Check Point Software Technologies Ltd — how do they compare? AbCellera Biologics Inc trades at $7.22 (market cap $2.35B), while Check Point Software Technologies Ltd trades at $136.37 (market cap $14.43B). The key difference: Check Point Software Technologies Ltd is far larger — about 6.1× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| ABCL | CHKP | |
|---|---|---|
Market Cap | $2.35B | $14.43B |
Sector | Health | Technology |
52-Week High | $8.12 | $231.23 |
52-Week Low | $2.78 | $112.47 |
Enterprise Value | $1.99B | $13.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CHKP trades at $138.87, up 1.68% today, with a bullish technical outlook supported by moving averages and strong support at $136. The company demonstrates robust fundamentals with a 38.37% net income margin, consistent earnings beats, and strategic AI partnerships enhancing its cybersecurity offerings. Recent news highlights ESG reporting and cloud security expansions.
Outlook remains positive with a consensus price target of $148.73, though risks include insider sales and legal investigations. The stock offers growth potential from AI integration but faces competitive and regulatory headwinds that warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
